Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 67 entries
Sorted by: Best Match Show Resources per page
An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses.

Cell reports. Medicine

Hong JP, Reynoso GV, Andhey PS, Swain A, Turner JS, Boon ACM, Krammer F, Ellebedy AH, Zanini F, Artyomov M, Hickman HD, Diamond MS.
PMID: 32699843
Cell Rep Med. 2020 Jun 23;1(3). doi: 10.1016/j.xcrm.2020.100035.

CD137 is a costimulatory receptor expressed on natural killer cells, T cells, and subsets of dendritic cells. An agonistic monoclonal antibody (mAb) against CD137 has been used to reduce tumor burden or reverse autoimmunity in animal models and clinical...

Cite
Hong JP, Reynoso GV, Andhey PS, et al. An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses. Cell Rep Med. 2020;1(3)doi: 10.1016/j.xcrm.2020.100035.
Hong, J. P., Reynoso, G. V., Andhey, P. S., Swain, A., Turner, J. S., Boon, A. C. M., Krammer, F., Ellebedy, A. H., Zanini, F., Artyomov, M., Hickman, H. D., & Diamond, M. S. (2020). An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses. Cell reports. Medicine, 1(3), . https://doi.org/10.1016/j.xcrm.2020.100035
Hong, Jun P, et al. "An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses." Cell reports. Medicine vol. 1,3 (2020). doi: https://doi.org/10.1016/j.xcrm.2020.100035
Hong JP, Reynoso GV, Andhey PS, Swain A, Turner JS, Boon ACM, Krammer F, Ellebedy AH, Zanini F, Artyomov M, Hickman HD, Diamond MS. An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses. Cell Rep Med. 2020 Jun 23;1(3). doi: 10.1016/j.xcrm.2020.100035. PMID: 32699843; PMCID: PMC7375459.
Copy Download .nbib Format: NLM
SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection.

medRxiv : the preprint server for health sciences

Klingler J, Lambert GS, Itri V, Liu S, Bandres JC, Enyindah-Asonye G, Liu X, Simon V, Gleason CR, Kleiner G, Chiu HP, Hung CT, Kowdle S, Amanat F, Lee B, Zolla-Pazner S, Upadhyay C, Hioe CE.
PMID: 34031663
medRxiv. 2021 May 17; doi: 10.1101/2021.05.11.21256972.

BACKGROUND: Mass vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is on-going in the United States with vaccines approved for emergency use by the FDA. Each vaccine can induce spike-specific antibodies (Abs) with virus-neutralizing activities; however, the Fc-mediated...

Cite
Klingler J, Lambert GS, Itri V, et al. SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection. medRxiv. 2021;doi: 10.1101/2021.05.11.21256972.
Klingler, J., Lambert, G. S., Itri, V., Liu, S., Bandres, J. C., Enyindah-Asonye, G., Liu, X., Simon, V., Gleason, C. R., Kleiner, G., Chiu, H. P., Hung, C. T., Kowdle, S., Amanat, F., Lee, B., Zolla-Pazner, S., Upadhyay, C., & Hioe, C. E. (2021). SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.05.11.21256972
Klingler, Jéromine, et al. "SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.05.11.21256972
Klingler J, Lambert GS, Itri V, Liu S, Bandres JC, Enyindah-Asonye G, Liu X, Simon V, Gleason CR, Kleiner G, Chiu HP, Hung CT, Kowdle S, Amanat F, Lee B, Zolla-Pazner S, Upadhyay C, Hioe CE. SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection. medRxiv. 2021 May 17; doi: 10.1101/2021.05.11.21256972. PMID: 34031663; PMCID: PMC8142663.
Copy Download .nbib Format: NLM
Mice with diverse microbial exposure histories as a model for preclinical vaccine testing.

Cell host & microbe

Fiege JK, Block KE, Pierson MJ, Nanda H, Shepherd FK, Mickelson CK, Stolley JM, Matchett WE, Wijeyesinghe S, Meyerholz DK, Vezys V, Shen SS, Hamilton SE, Masopust D, Langlois RA.
PMID: 34731647
Cell Host Microbe. 2021 Dec 08;29(12):1815-1827.e6. doi: 10.1016/j.chom.2021.10.001. Epub 2021 Nov 02.

Laboratory mice comprise an expeditious model for preclinical vaccine testing; however, vaccine immunogenicity in these models often inadequately translates to humans. Reconstituting physiologic microbial experience to specific pathogen-free (SPF) mice induces durable immunological changes that better recapitulate human immunity....

Cite
Fiege JK, Block KE, Pierson MJ, et al. Mice with diverse microbial exposure histories as a model for preclinical vaccine testing. Cell Host Microbe. 2021;29(12):1815-1827.e6doi: 10.1016/j.chom.2021.10.001.
Fiege, J. K., Block, K. E., Pierson, M. J., Nanda, H., Shepherd, F. K., Mickelson, C. K., Stolley, J. M., Matchett, W. E., Wijeyesinghe, S., Meyerholz, D. K., Vezys, V., Shen, S. S., Hamilton, S. E., Masopust, D., & Langlois, R. A. (2021). Mice with diverse microbial exposure histories as a model for preclinical vaccine testing. Cell host & microbe, 29(12), 1815-1827.e6. https://doi.org/10.1016/j.chom.2021.10.001
Fiege, Jessica K, et al. "Mice with diverse microbial exposure histories as a model for preclinical vaccine testing." Cell host & microbe vol. 29,12 (2021): 1815-1827.e6. doi: https://doi.org/10.1016/j.chom.2021.10.001
Fiege JK, Block KE, Pierson MJ, Nanda H, Shepherd FK, Mickelson CK, Stolley JM, Matchett WE, Wijeyesinghe S, Meyerholz DK, Vezys V, Shen SS, Hamilton SE, Masopust D, Langlois RA. Mice with diverse microbial exposure histories as a model for preclinical vaccine testing. Cell Host Microbe. 2021 Dec 08;29(12):1815-1827.e6. doi: 10.1016/j.chom.2021.10.001. Epub 2021 Nov 02. PMID: 34731647; PMCID: PMC8665115.
Copy Download .nbib Format: NLM
Development of a Macrophage-Based ADCC Assay.

Vaccines

Uccellini MB, Aslam S, Liu STH, Alam F, García-Sastre A.
PMID: 34204268
Vaccines (Basel). 2021 Jun 17;9(6). doi: 10.3390/vaccines9060660.

Fc-dependent effector functions are an important determinant of the in vivo potency of therapeutic antibodies. Effector function is determined by the combination of FcRs bound by the antibody and the cell expressing the relevant FcRs, leading to antibody-dependent cellular...

Cite
Uccellini MB, Aslam S, Liu STH, et al. Development of a Macrophage-Based ADCC Assay. Vaccines (Basel). 2021;9(6)doi: 10.3390/vaccines9060660.
Uccellini, M. B., Aslam, S., Liu, S. T. H., Alam, F., & García-Sastre, A. (2021). Development of a Macrophage-Based ADCC Assay. Vaccines, 9(6), . https://doi.org/10.3390/vaccines9060660
Uccellini, Melissa B, et al. "Development of a Macrophage-Based ADCC Assay." Vaccines vol. 9,6 (2021). doi: https://doi.org/10.3390/vaccines9060660
Uccellini MB, Aslam S, Liu STH, Alam F, García-Sastre A. Development of a Macrophage-Based ADCC Assay. Vaccines (Basel). 2021 Jun 17;9(6). doi: 10.3390/vaccines9060660. PMID: 34204268; PMCID: PMC8234572.
Copy Download .nbib Format: NLM
The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters.

Research square

Diamond M, Halfmann P, Maemura T, Iwatsuki-Horimoto K, Iida S, Kiso M, Scheaffer S, Darling T, Joshi A, Loeber S, Foster S, Ying B, Whitener B, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Li R, Sakai Y, Liu Y, Larson D, Osorio J, Hernandez-Ortiz J, ÄŒiuoderis K, Florek K, Patel M, Bateman A, Odle A, Wong LY, Wang Z, Edara VV, Chong Z, Thackray L, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby R, Seder R, Suthar M, Garcia-Sastre A, Schotsaert M, Suzuki T, Boon A, Kawaoka Y, Douek D, Moliva J, Sullivan N, Gagne M, Ransier A, Case J, Jeevan T, Franks J, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Singh G, Warang P, Gonzalez-Reiche AS, Sordillo E, van Bakel H, Simon V.
PMID: 34981044
Res Sq. 2021 Dec 29; doi: 10.21203/rs.3.rs-1211792/v1.

Despite the development and deployment of antibody and vaccine countermeasures, rapidly-spreading SARS-CoV-2 variants with mutations at key antigenic sites in the spike protein jeopardize their efficacy. The recent emergence of B.1.1.529, the Omicron variant1,2, which has more than 30...

Cite
Diamond M, Halfmann P, Maemura T, et al. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Res Sq. 2021;doi: 10.21203/rs.3.rs-1211792/v1.
Diamond, M., Halfmann, P., Maemura, T., Iwatsuki-Horimoto, K., Iida, S., Kiso, M., Scheaffer, S., Darling, T., Joshi, A., Loeber, S., Foster, S., Ying, B., Whitener, B., Floyd, K., Ujie, M., Nakajima, N., Ito, M., Wright, R., Uraki, R., Li, R., Sakai, Y., Liu, Y., Larson, D., Osorio, J., Hernandez-Ortiz, J., ÄŒiuoderis, K., Florek, K., Patel, M., Bateman, A., Odle, A., Wong, L. Y., Wang, Z., Edara, V. V., Chong, Z., Thackray, L., Ueki, H., Yamayoshi, S., Imai, M., Perlman, S., Webby, R., Seder, R., Suthar, M., Garcia-Sastre, A., Schotsaert, M., Suzuki, T., Boon, A., Kawaoka, Y., Douek, D., Moliva, J., Sullivan, N., Gagne, M., Ransier, A., Case, J., Jeevan, T., Franks, J., Fabrizio, T., DeBeauchamp, J., Kercher, L., Seiler, P., Singh, G., Warang, P., Gonzalez-Reiche, A. S., Sordillo, E., van Bakel, H., & Simon, V. (2021). The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Research square, . https://doi.org/10.21203/rs.3.rs-1211792/v1
Diamond, Michael, et al. "The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters." Research square vol. (2021). doi: https://doi.org/10.21203/rs.3.rs-1211792/v1
Diamond M, Halfmann P, Maemura T, Iwatsuki-Horimoto K, Iida S, Kiso M, Scheaffer S, Darling T, Joshi A, Loeber S, Foster S, Ying B, Whitener B, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Li R, Sakai Y, Liu Y, Larson D, Osorio J, Hernandez-Ortiz J, ÄŒiuoderis K, Florek K, Patel M, Bateman A, Odle A, Wong LY, Wang Z, Edara VV, Chong Z, Thackray L, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby R, Seder R, Suthar M, Garcia-Sastre A, Schotsaert M, Suzuki T, Boon A, Kawaoka Y, Douek D, Moliva J, Sullivan N, Gagne M, Ransier A, Case J, Jeevan T, Franks J, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Singh G, Warang P, Gonzalez-Reiche AS, Sordillo E, van Bakel H, Simon V. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Res Sq. 2021 Dec 29; doi: 10.21203/rs.3.rs-1211792/v1. PMID: 34981044; PMCID: PMC8722607.
Copy Download .nbib Format: NLM
Differential T cell reactivity to seasonal coronaviruses and SARS-CoV-2 in community and health care workers.

medRxiv : the preprint server for health sciences

da Silva Antunes R, Pallikkuth S, Williams E, Yu ED, Mateus J, Quiambao L, Wang E, Rawlings SA, Stadlbauer D, Jiang K, Amanat F, Arnold D, Andrews D, Fuego I, Dan JM, Grifoni A, Weiskopf D, Krammer F, Crotty S, Hoffer ME, Pahwa SG, Sette A.
PMID: 33469594
medRxiv. 2021 Jan 15; doi: 10.1101/2021.01.12.21249683.

Herein we measured CD4

Cite
da Silva Antunes R, Pallikkuth S, Williams E, et al. Differential T cell reactivity to seasonal coronaviruses and SARS-CoV-2 in community and health care workers. medRxiv. 2021;doi: 10.1101/2021.01.12.21249683.
da Silva Antunes, R., Pallikkuth, S., Williams, E., Yu, E. D., Mateus, J., Quiambao, L., Wang, E., Rawlings, S. A., Stadlbauer, D., Jiang, K., Amanat, F., Arnold, D., Andrews, D., Fuego, I., Dan, J. M., Grifoni, A., Weiskopf, D., Krammer, F., Crotty, S., Hoffer, M. E., Pahwa, S. G., & Sette, A. (2021). Differential T cell reactivity to seasonal coronaviruses and SARS-CoV-2 in community and health care workers. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.01.12.21249683
da Silva Antunes, Ricardo, et al. "Differential T cell reactivity to seasonal coronaviruses and SARS-CoV-2 in community and health care workers." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.01.12.21249683
da Silva Antunes R, Pallikkuth S, Williams E, Yu ED, Mateus J, Quiambao L, Wang E, Rawlings SA, Stadlbauer D, Jiang K, Amanat F, Arnold D, Andrews D, Fuego I, Dan JM, Grifoni A, Weiskopf D, Krammer F, Crotty S, Hoffer ME, Pahwa SG, Sette A. Differential T cell reactivity to seasonal coronaviruses and SARS-CoV-2 in community and health care workers. medRxiv. 2021 Jan 15; doi: 10.1101/2021.01.12.21249683. PMID: 33469594; PMCID: PMC7814840.
Copy Download .nbib Format: NLM
SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection.

medRxiv : the preprint server for health sciences

Klingler J, Lambert GS, Itri V, Liu S, Bandres JC, Enyindah-Asonye G, Liu X, Oguntuyo KY, Amanat F, Lee B, Zolla-Pazner S, Upadhyay C, Hioe CE.
PMID: 34031663
medRxiv. 2021 May 17; doi: 10.1101/2021.05.11.21256972.

BACKGROUND: Mass vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is on-going in the United States with vaccines approved for emergency use by the FDA. Each vaccine can induce spike-specific antibodies (Abs) with virus-neutralizing activities; however, the Fc-mediated...

Cite
Klingler J, Lambert GS, Itri V, et al. SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection. medRxiv. 2021;doi: 10.1101/2021.05.11.21256972.
Klingler, J., Lambert, G. S., Itri, V., Liu, S., Bandres, J. C., Enyindah-Asonye, G., Liu, X., Oguntuyo, K. Y., Amanat, F., Lee, B., Zolla-Pazner, S., Upadhyay, C., & Hioe, C. E. (2021). SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.05.11.21256972
Klingler, Jéromine, et al. "SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.05.11.21256972
Klingler J, Lambert GS, Itri V, Liu S, Bandres JC, Enyindah-Asonye G, Liu X, Oguntuyo KY, Amanat F, Lee B, Zolla-Pazner S, Upadhyay C, Hioe CE. SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection. medRxiv. 2021 May 17; doi: 10.1101/2021.05.11.21256972. PMID: 34031663; PMCID: PMC8142663.
Copy Download .nbib Format: NLM
Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model.

bioRxiv : the preprint server for biology

Amanat F, Strohmeier S, Rathnasinghe R, Schotsaert M, Coughlan L, García-Sastre A, Krammer F.
PMID: 32995785
bioRxiv. 2020 Sep 17; doi: 10.1101/2020.09.16.300970.

The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the prime target for vaccine development. The spike protein mediates both binding to host cells and membrane fusion and is also so far the...

Cite
Amanat F, Strohmeier S, Rathnasinghe R, et al. Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model. bioRxiv. 2020;doi: 10.1101/2020.09.16.300970.
Amanat, F., Strohmeier, S., Rathnasinghe, R., Schotsaert, M., Coughlan, L., García-Sastre, A., & Krammer, F. (2020). Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2020.09.16.300970
Amanat, Fatima, et al. "Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model." bioRxiv : the preprint server for biology vol. (2020). doi: https://doi.org/10.1101/2020.09.16.300970
Amanat F, Strohmeier S, Rathnasinghe R, Schotsaert M, Coughlan L, García-Sastre A, Krammer F. Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model. bioRxiv. 2020 Sep 17; doi: 10.1101/2020.09.16.300970. PMID: 32995785; PMCID: PMC7523111.
Copy Download .nbib Format: NLM
Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Rolfo C, Meshulami N, Russo A, Krammer F, García-Sastre A, Mack PC, Gomez JE, Bhardwaj N, Benyounes A, Sirera R, Moore A, Rohs N, Henschke CI, Yankelevitz D, King J, Shyr Y, Bunn PA, Minna JD, Hirsch FR.
PMID: 34774792
J Thorac Oncol. 2021 Nov 10; doi: 10.1016/j.jtho.2021.11.001. Epub 2021 Nov 10.

Patients with lung cancer are especially vulnerable to coronavirus disease 2019 (COVID-19) with a greater than sevenfold higher rate of becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19, a greater than threefold higher hospitalization rate with...

Cite
Rolfo C, Meshulami N, Russo A, et al. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. J Thorac Oncol. 2021;doi: 10.1016/j.jtho.2021.11.001.
Rolfo, C., Meshulami, N., Russo, A., Krammer, F., García-Sastre, A., Mack, P. C., Gomez, J. E., Bhardwaj, N., Benyounes, A., Sirera, R., Moore, A., Rohs, N., Henschke, C. I., Yankelevitz, D., King, J., Shyr, Y., Bunn, P. A., Minna, J. D., & Hirsch, F. R. (2021). Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, . https://doi.org/10.1016/j.jtho.2021.11.001
Rolfo, Christian, et al. "Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. (2021). doi: https://doi.org/10.1016/j.jtho.2021.11.001
Rolfo C, Meshulami N, Russo A, Krammer F, García-Sastre A, Mack PC, Gomez JE, Bhardwaj N, Benyounes A, Sirera R, Moore A, Rohs N, Henschke CI, Yankelevitz D, King J, Shyr Y, Bunn PA, Minna JD, Hirsch FR. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. J Thorac Oncol. 2021 Nov 10; doi: 10.1016/j.jtho.2021.11.001. Epub 2021 Nov 10. PMID: 34774792; PMCID: PMC8579698.
Copy Download .nbib Format: NLM
Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms.

iScience

Carreño JM, Mendu DR, Simon V, Shariff MA, Singh G, Menon V, Krammer F.
PMID: 34368647
iScience. 2021 Sep 24;24(9):102937. doi: 10.1016/j.isci.2021.102937. Epub 2021 Jul 31.

Current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests are based on the full-length spike (S), the receptor-binding domain (RBD), or the nucleoprotein (NP) as substrates. Here, we used samples from healthcare workers (HCWs) to perform a longitudinal...

Cite
Carreño JM, Mendu DR, Simon V, et al. Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms. iScience. 2021;24(9):102937doi: 10.1016/j.isci.2021.102937.
Carreño, J. M., Mendu, D. R., Simon, V., Shariff, M. A., Singh, G., Menon, V., & Krammer, F. (2021). Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms. iScience, 24(9), 102937. https://doi.org/10.1016/j.isci.2021.102937
Carreño, Juan Manuel, et al. "Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms." iScience vol. 24,9 (2021): 102937. doi: https://doi.org/10.1016/j.isci.2021.102937
Carreño JM, Mendu DR, Simon V, Shariff MA, Singh G, Menon V, Krammer F. Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms. iScience. 2021 Sep 24;24(9):102937. doi: 10.1016/j.isci.2021.102937. Epub 2021 Jul 31. PMID: 34368647; PMCID: PMC8324485.
Copy Download .nbib Format: NLM
Mice with diverse microbial exposure histories as a model for preclinical vaccine testing.

Cell host & microbe

Fiege JK, Block KE, Pierson MJ, Nanda H, Shepherd FK, Mickelson CK, Stolley JM, Matchett WE, Wijeyesinghe S, Meyerholz DK, Vezys V, Shen SS, Hamilton SE, Masopust D, Langlois RA.
PMID: 34731647
Cell Host Microbe. 2021 Dec 08;29(12):1815-1827.e6. doi: 10.1016/j.chom.2021.10.001. Epub 2021 Nov 02.

Laboratory mice comprise an expeditious model for preclinical vaccine testing; however, vaccine immunogenicity in these models often inadequately translates to humans. Reconstituting physiologic microbial experience to specific pathogen-free (SPF) mice induces durable immunological changes that better recapitulate human immunity....

Cite
Fiege JK, Block KE, Pierson MJ, et al. Mice with diverse microbial exposure histories as a model for preclinical vaccine testing. Cell Host Microbe. 2021;29(12):1815-1827.e6doi: 10.1016/j.chom.2021.10.001.
Fiege, J. K., Block, K. E., Pierson, M. J., Nanda, H., Shepherd, F. K., Mickelson, C. K., Stolley, J. M., Matchett, W. E., Wijeyesinghe, S., Meyerholz, D. K., Vezys, V., Shen, S. S., Hamilton, S. E., Masopust, D., & Langlois, R. A. (2021). Mice with diverse microbial exposure histories as a model for preclinical vaccine testing. Cell host & microbe, 29(12), 1815-1827.e6. https://doi.org/10.1016/j.chom.2021.10.001
Fiege, Jessica K, et al. "Mice with diverse microbial exposure histories as a model for preclinical vaccine testing." Cell host & microbe vol. 29,12 (2021): 1815-1827.e6. doi: https://doi.org/10.1016/j.chom.2021.10.001
Fiege JK, Block KE, Pierson MJ, Nanda H, Shepherd FK, Mickelson CK, Stolley JM, Matchett WE, Wijeyesinghe S, Meyerholz DK, Vezys V, Shen SS, Hamilton SE, Masopust D, Langlois RA. Mice with diverse microbial exposure histories as a model for preclinical vaccine testing. Cell Host Microbe. 2021 Dec 08;29(12):1815-1827.e6. doi: 10.1016/j.chom.2021.10.001. Epub 2021 Nov 02. PMID: 34731647; PMCID: PMC8665115.
Copy Download .nbib Format: NLM
Influenza immune escape under heterogeneous host immune histories.

Trends in microbiology

Oidtman RJ, Arevalo P, Bi Q, McGough L, Russo CJ, Vera Cruz D, Costa Vieira M, Gostic KM.
PMID: 34218981
Trends Microbiol. 2021 Dec;29(12):1072-1082. doi: 10.1016/j.tim.2021.05.009. Epub 2021 Jul 01.

In a pattern called immune imprinting, individuals gain the strongest immune protection against the influenza strains encountered earliest in life. In many recent examples, differences in early infection history can explain birth year-associated differences in susceptibility (cohort effects). Susceptibility...

Cite
Oidtman RJ, Arevalo P, Bi Q, et al. Influenza immune escape under heterogeneous host immune histories. Trends Microbiol. 2021;29(12):1072-1082doi: 10.1016/j.tim.2021.05.009.
Oidtman, R. J., Arevalo, P., Bi, Q., McGough, L., Russo, C. J., Vera Cruz, D., Costa Vieira, M., & Gostic, K. M. (2021). Influenza immune escape under heterogeneous host immune histories. Trends in microbiology, 29(12), 1072-1082. https://doi.org/10.1016/j.tim.2021.05.009
Oidtman, Rachel J, et al. "Influenza immune escape under heterogeneous host immune histories." Trends in microbiology vol. 29,12 (2021): 1072-1082. doi: https://doi.org/10.1016/j.tim.2021.05.009
Oidtman RJ, Arevalo P, Bi Q, McGough L, Russo CJ, Vera Cruz D, Costa Vieira M, Gostic KM. Influenza immune escape under heterogeneous host immune histories. Trends Microbiol. 2021 Dec;29(12):1072-1082. doi: 10.1016/j.tim.2021.05.009. Epub 2021 Jul 01. PMID: 34218981; PMCID: PMC8578193.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 67 entries